Financial Conflict of Interest (FCOI) Policy
Persons covered by this Policy
This policy applies to all employees, including all full-time, part-time, temporary, and contract employees, of Reactive Biosciences, Inc. who are planning to participate in, or are participating in, Public Health Service (“PHS”) funded research by means of a grant or cooperative agreement.
1. The primary goal of this policy is to promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct, and reporting of research funded under Public Health Service (PHS) grants or cooperative agreements will be free from bias resulting from Investigator financial conflicts of interest and to prevent an employee’s activities from adversely influencing Reactive Biosciences, Inc. operations.
2. It is recognized that research related conflicts of interest can arise from legitimate and appropriate activities including economic development, public-private interactions, and employee’s and their family’s personal business relationships.
3. This policy is implemented in accordance with 42 CFR Part 50 Subpart F – “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought” and 45 CFR Part 94 “Responsible Prospective Contractors” as well as all other relevant policies of federal funding and oversight agencies.
A. Statement of general policy
1. The design, conduct, and reporting of Research funded under Public Health Service (PHS) grants or cooperative agreements should be free from bias resulting from Investigator financial conflicts of interest.
2. To provide a reasonable expectation of achieving the goal of this policy, Investigators shall complete appropriate training as required under this policy; Investigators shall disclose perceived and real conflicts of interest annually and provide new or updated disclosures in a timely manner; Reactive Biosciences, Inc. shall provide for the elimination or management of Financial Conflicts of Interest; and Reactive Biosciences, Inc. shall make disclosures to both the PHS and to the public as required under this policy.
3. Nothing in this policy shall be construed to permit, even with disclosure, any activity that is prohibited by law.
4. For matters subject to this policy, to the extent of any conflict between this policy and provisions of the general Reactive Biosciences, Inc. Conflict of Interest Policy, this policy shall control.
5. Nothing in this policy shall be construed to limit or abridge the authority of Reactive Biosciences, Inc. management to take such action as they deem appropriate regardless of any action or inaction by an employee of Reactive Biosciences, Inc..
Institution refers to Reactive Biosciences, Inc..
Investigator means the project director or principal Investigator (PD/PI) and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded by the PHS, or proposed for such funding, which may include, for example, collaborators or consultants.
Institutional responsibilities mean an Investigator’s professional responsibilities on behalf of the Institution, and as defined by the Institution, including, but not limited to, activities such as research, research consultation, teaching, professional practice, institutional committee memberships, and service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards.
Financial interest means anything of monetary value, whether the value is readily ascertainable.
Financial Conflict of Interest (FCOI) means a significant financial interest that could directly and significantly affect the design, conduct, or reporting of the NIH-funded research.
Manage means taking action to address a financial conflict of interest, which can include reducing or eliminating the financial conflict of interest, to ensure, to the extent possible, that the design, conduct, and reporting of research will be free from bias.
Senior/Key Personnel means the Project Director/Principal Investigator (PD/PI) and any other person identified as senior/key personnel by the Institution in the grant application, progress report, or any other report submitted to the NIH by the Institution under the regulation.
Significant Financial Interest (SFI) is defined by the regulation as:
(1) A financial interest consisting of one or more of the following interests of the Investigator (and those of the Investigator’s spouse and dependent children) that reasonably appears to be related to the Investigator’s institutional responsibilities:
(i) Regarding any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. For purposes of this definition, remuneration includes salary and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship); equity interest includes any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value;
(ii) Regarding any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (or the Investigator’s spouse or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest); or
(iii) Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of income related to such rights and interests.
(2) Investigators also must disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of the Investigator and not reimbursed to the Investigator so that the exact monetary value may not be readily available), related to their institutional responsibilities; provided, however, that this disclosure requirement does not apply to travel that is reimbursed or sponsored by a federal, state, or local government agency, an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education. The Institution’s FCOI policy will specify the details of this disclosure, which will include, at a minimum, the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration. In accordance with the Institution’s FCOI policy, the institutional official(s) will determine if further information is needed, including a determination or disclosure of monetary value, to determine whether the travel constitutes an FCOI with the PHS-funded research.
(3) The term significant financial interest does not include the following types of financial interests: salary, royalties, or other remuneration paid by the Institution to the Investigator if the Investigator is currently employed or otherwise appointed by the Institution, including intellectual property rights assigned to the Institution and agreements to share in royalties related to such rights; any ownership interest in the Institution held by the Investigator, if the Institution is a commercial or for-profit organization; income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles; income from seminars, lectures, or teaching engagements sponsored by a federal, state, or local government agency, an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education; or income from service on advisory committees or review panels for a federal, state, or local government agency, an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.
C. Policy Implementation
1. Training Required: Investigators shall complete FCOI training provided by the Institution on or before their becoming subject to this policy and then at least every four (4) years thereafter. Currently, Reactive Biosciences, Inc. uses the NIH web-based training which can be accessed at: (http://grants.nih.gov/grants/policy/coi/tutorial2011/fcoi.htm). Investigators must save and print the FCOI Certificate as proof of completion. Immediate training will be required if the Institution revises this policy in a manner that affects the Investigator, when an Investigator is new to the Institution, or because of a finding of noncompliance with this policy or a management plan, or other related misconduct.
2. Disclosure Requirement:
(a) An Investigator shall disclose any situation in which the Investigator has, or may have, a real or potential Significant Financial Interest as defined and provided for herein. Research should not be undertaken where a Significant Financial Interest is present until a determination and approval has been made pursuant to this policy.
(b) Investigators shall keep their supervisors informed of the Investigator’s Significant Financial Interest. If a supervisor becomes aware of a conflict of interest that an employee has not disclosed, the supervisor shall discuss the situation with the employee, require that a written disclosure be made as provided in this policy, and inform Reactive Biosciences, Inc. to anticipate the receipt of a new Disclosure.
3. Disclosure Frequency:
(a) Disclosure must be made annually to Reactive Biosciences, Inc.. If no Significant Financial Interest is present a Disclosure must still be submitted that states “none”. The date such annual Disclosure is due shall be set by the Reactive Biosciences, Inc. and disseminated campus wide.
(b) In addition to the annual Disclosure, a new or updated Disclosure must be completed in a timely manner whenever a new or potential Significant Financial Interest arises or when a significant change occurs concerning an existing Disclosure.
(c) In any event, Disclosure must be made within thirty (30) days of discovery or acquiring a new Significant Financial Interest.
(d) Newly hired Investigators should make a Disclosure as part of their new hire employment process.
4. Review and Management:
(a) The Institution shall appoint and authorize a committee of appropriate composition and skills to review the Disclosure and determine if it is a FCOI. This committee shall be known as the Research Conflict of Interest Committee (“Committee”) and serve at the pleasure of the Institution.
(b) If a determination is made that a FCOI exists, the Committee shall seek input from the Investigator and recommend to the Institution a suitable action plan (“Management Plan”) to eliminate or manage the FCOI consistent with the objectives of this policy. The Management Plan shall provide for its periodic review and updating at least annually. If there is no reasonable way to manage a FCOI then the Investigator may be prohibited from participating in the related Research until such a time as the FCOI is eliminated.
(c) Examples of conditions or restrictions that might be imposed to manage a financial conflict of interest include, but are not limited to:
(i) Public disclosure of financial conflicts of interest (e.g., when presenting or publishing the research);
(ii) For research projects involving human subjects research, disclosure of financial conflicts of interest directly to participants;
(iii) Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the research against bias resulting from the financial conflict of interest;
(iv) Modification of the research plan;
(v) Change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research;
(vi) Reduction or elimination of the financial interest (e.g. sale of an equity interest);or (vii) Severance of relationships that create financial conflicts.
(d) The Institution shall review the proposed Management Plan and can approve, modify, and approve, or return to the Committee for additional work. Final review and determination must be completed prior to the expenditure of any PHS funds for the applicable Research.
D. Violations and Sanctions
1. Sanctions: Violations of Institution policies, including the failure to avoid a prohibited activity or disclose a conflict of interest in a timely manner, will be dealt with in accordance with applicable policies and procedures that may include disciplinary actions up to and including termination of employment.
2. Retrospective Review:
(a) The Institution shall complete retrospective reviews of determinations of noncompliance with this policy within 120 days of the determination.
(b) The retrospective reviews shall be documented; such documentation shall include, but not necessarily be limited to, all of the following key elements: 1. Project number; 2. Project title; 3. PD/PI or contact PD/PI if a multiple PD/PI model is used; 4. Name of the Investigator with the FCOI; 5. Name of the entity with which the Investigator has a financial conflict of interest; 6. Reason(s) for the retrospective review; 7. Detailed methodology used for the retrospective review (e.g., methodology of the review process, composition of the review panel, documents reviewed); 8. Findings of the review; and 9. Conclusions of the review.
(c) Based on the results of the retrospective review, if appropriate, the Institution shall update the previously submitted FCOI report, specifying the actions that will be taken to manage the financial conflict of interest going forward.
(d) If bias is found, the Institution is required to notify the PHS Awarding Component promptly and submit a mitigation report to the PHS Awarding Component. The mitigation report must include, at a minimum, the key elements documented in the retrospective review above and a description of the impact of the bias on the research project and the Institution’s plan of action or actions taken to eliminate or mitigate the effect of the bias (e.g., impact on the research project; extent of harm done, including any qualitative and quantitative data to support any actual or future harm; analysis of whether the research project is salvageable). Thereafter, the Institution will submit FCOI reports annually. Depending on the nature of the financial conflict of interest, the Institution may determine that additional interim measures are necessary with regard to the Investigator’s participation in the PHS-funded research project between the date that the financial conflict of interest or the Investigator’s noncompliance is determined and the completion of the Institution’s retrospective review.
3. Clinical Research: In any case in which the HHS determines that a PHS-funded project of clinical research whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by an Investigator with a FCOI that was not managed or reported by the Institution as required by this policy, Reactive Biosciences, Inc. shall require the Investigator involved to disclose the FCOI in each public presentation of the results of the research and to request an addendum to previously published presentations.
E. Institutional Reporting
1. The Institution shall provide the initial, annual and revised reports of FCOI to PHS/National Institutes of Health (NIH) per the applicable regulations.
2. The Institution shall notify PHS/NIH of bias found in the design, conduct, or reporting of PHS/NIH funded Research including whether Investigator failure to comply with this FCOI policy or management plan appears to have caused such bias.
3. Records shall be maintained for at least three (3) years from the submission of the final expenditure reports for the pertinent PHS/NIH funding or, where applicable, from other dates specified in 45 C.F.R. 75.361 (see FAQ A.11) for different situations.
4. FCOI Informational requests by the public should be made to the Institution. The Institution shall respond to requests for FCOI information within five (5) business days as provided for under applicable regulations.
F. Sub recipients
Institution shall comply with all pertinent sub-recipient FCOI requirements as mandated by PHS regulation, when applicable.
G. Public Accessibility
This FCOI policy will be made publicly accessible on the company’s website.
Information concerning identified FCOIs held by senior/key personnel, as defined by 42 CFR Part 50 Subpart F, will be made publicly accessible prior to the expenditure of funds. The publicly accessible information will:
1. Include the minimum elements as provided in 42 CFR Part 50 Subpart F.
2. Be made available within 5 business days of a written request.
3. Be updated at least annually, but a response to a written request must be current.
4. Be updated within 60 days of a newly identified FCOI, but a response to a written request must be current.